Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159580 | 0.91 | CYP2D6 (0.46) | CYP2D6SRCHPGDLMNAMAPK1 | |
| SCHEMBL9671856 | 0.91 | CYP2D6 (0.46) | CYP2D6SRCHPGDLMNAMAPK1 | |
| SCHEMBL6279955 | 0.88 | ALOX5 (0.46) | CYP2D6SRCHPGDLMNAALOX5 | |
| SCHEMBL3236310 | 0.85 | KMT2A (0.56) | LMNAKMT2AMMECYP3A4 | |
| SCHEMBL2454614 | 0.84 | CYP2D6 (0.52) | CYP2D6SRCHPGDLMNAMAPK1 | |
| SCHEMBL4568744 | 0.82 | CYP3A4 (0.49) | CYP2D6SRCHPGDLMNAMAPK1 | |
| SCHEMBL15342224 | 0.82 | CYP3A4 (0.49) | CYP2D6SRCHPGDLMNAMAPK1 | |
| SCHEMBL11458679 | 0.82 | MMP8 (0.50) | LMNAKMT2ACYP3A4 | |
| SCHEMBL28213572 | 0.80 | CYP2D6 (0.43) | CYP2D6SRCLMNAMAPK1ALOX5 | |
| SCHEMBL14960669 | 0.80 | HPGD (0.47) | CYP2D6SRCHPGDLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447246-B2 | Method of covalently bonding an organic metal complex to a polymer | CYNORA GMBH (DE) | 2016-09-20 | — | — | US | disclosed |
| US-9447245-B2 | Cross-linking and stabilization of organic metal complexes in networks | CYNORA GMBH (DE) | 2016-09-20 | — | — | US | disclosed |
| US-9447245-B2 | Cross-linking and stabilization of organic metal complexes in networks | CYNORA GMBH (DE) | 2016-09-20 | — | — | US | disclosed |
| US-9447246-B2 | Method of covalently bonding an organic metal complex to a polymer | CYNORA GMBH (DE) | 2016-09-20 | — | — | US | disclosed |
| EP-2729506-B1 | METHOD FOR COVALENT BINDING OF A METAL COMPOUND TO A POLYMER | CYNORA GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2729505-B1 | METHOD FOR COVALENT BINDING OF A METAL COMPOUND TO A POLYMER | CYNORA GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-20140142259-A1 | METHOD OF COVALENTLY BONDING AN ORGANIC METAL COMPLEX TO A POLYMER | CYNORA GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142258-A1 | CROSS-LINKING AND STABILIZATION OF ORGANIC METAL COMPLEXES IN NETWORKS | CYNORA GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142258-A1 | CROSS-LINKING AND STABILIZATION OF ORGANIC METAL COMPLEXES IN NETWORKS | CYNORA GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142259-A1 | METHOD OF COVALENTLY BONDING AN ORGANIC METAL COMPLEX TO A POLYMER | CYNORA GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| WO-2004096808-A1 | TRIAZINE COMPOUNDS AND THEIR USE | DE NOVO PHARMACEUTICALS LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142259-A1 | METHOD OF COVALENTLY BONDING AN ORGANIC METAL COMPLEX TO A POLYMER | PICALM, LIG4, OSTC | CYP2D6 894/4885SRC 2577/4885HPGD 1141/4885 |
| US-20140142258-A1 | CROSS-LINKING AND STABILIZATION OF ORGANIC METAL COMPLEXES IN NETWORKS | SOD1, MTCL3, LIG4 | CYP2D6 933/4885SRC 2331/4885HPGD 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.